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Abstract. The chemical nature of most of the mycotoxins 
makes them highly liposoluble compounds that can be 
absorbed from the site of exposure such as from the gastro-
intestinal and respiratory tract to the blood stream where it 
can be dissimilated throughout the body and reach different 
organs such as the liver and kidneys. Mycotoxins have a strong 
tendency and ability to penetrate the human and animal cells 
and reach the cellular genome where it causes a major muta-
genic change in the nucleotide sequence which leads to strong 
and permanent defects in the genome. This defect will even-
tually be transcribed, translated and lead to the development 
of cancer. In this review, the chemical and physical nature of 
mycotoxins, the action of mycotoxins on the cellular genome 
and its effect on humans, mycotoxins and their carcinogenicity 
and mycotoxins research gaps are discussed, and new research 
areas are suggested. The research review posed various ques-
tions. What are the different mycotoxins that can cause cancer, 
what is the role of mycotoxins in causing cancer and what 
types of cancers can be caused by mycotoxins? These ques-
tions have been selected due to the significant increase in the 
mycotoxin contamination and the cancer incidence rate in the 
contemporary world. By revealing and understanding the role 
of mycotoxins in developing cancer, measures to reduce the 
risks and incidents of cancer could be taken.
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1. Introduction
Many chemical mutagens were proven to cause mutation 
and inactivation of the cancer suppressor genes such as P53, 
BRCA1 and BRCA2. One of the most influential chemical 
compounds that could cause a mutation in these genes are 
the mycotoxins (1). Mycotoxins are carcinogenic toxins that 
are produced by many Aspergillus and Penicillium species 
growing on food commodities (1). Among the different 
mycotoxins, aflatoxin B1 has been reported as the highest 
carcinogenic mycotoxin (2) and aflatoxin B1 can penetrate the 
cell membrane and attach to its DNA where it causes irrevers-
ible mutations (2). The chemical nature of aflatoxins makes it 
a highly liposoluble compound that can be absorbed from the 
site of exposure such as from the gastrointestinal and respira-
tory tract to the blood stream where it can move throughout the 
body (3). The exposure to these carcinogenic mycotoxins can 
be through the ingestion of the contaminated food that ends 
up in the stomach where it gets absorbed or by inhaling the 
dust particles of aflatoxins B1 from the food that is contami-
nated with these aflatoxins (3). Once the aflatoxins enter 
the cells, they are metabolized by the action of cytochrome 
P450, a microsomal enzyme to aflatoxin-8, 9-epoxide in the 
detoxification metabolic pathway for aflatoxins. It is highly 
reactive and unstable and requires the binding to a DNA or to 
the protein molecule in order to become more stable (3). Once 
the highly unstable aflatoxin-8, 9-epoxide binds to the DNA 
molecule with high affinity, it forms aflatoxin-N7-guanine that 
cause a guanine (G) to thymine (T) transversion mutations 
which will directly affect the cell cycle by affecting the P53 
gene which carries the codes for tumor suppressor proteins, 
meant to inhibit the development of tumors and cancers (3).
The role of aflatoxin B1 in causing mutation in the humans 
genome was extensively studied (2), many other mycotoxins 
are yet to be investigated to understand their method of action 
once they are in contact with the humans genome. This is 
particularly crucial because many mycotoxins have a closely 
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related chemical composition and similar functions inside the 
human body. The researchers decided on two research ques-
tions in this review that accurately describe the objectives of 
this research: What are the different types of mycotoxins that 
can cause cancer? What is the role of mycotoxins in causing 
cancer and what types of cancers can be caused by mycotoxins?
The reason for this review is due to the fact that there is 
an increase in mycotoxin contamination in the world and by 
understanding the role of different mycotoxins in the human 
body and their levels of toxicity and carcinogenicity, many 
new measures could be followed and many human lives and 
animals alike could be saved. In addition, there is a gap in 
cancer studies relating to mycotoxins as it has been only 
related to liver cancer (4). Although due to the similarity in 
nature and functions, mycotoxins can be related to many types 
of cancer. This review will concentrate on the previously 
published studies that answer both of our research questions 
and build on the arguments that support these questions.
2. Types of mycotoxins and their natural commodities
In an experiment done by El-Banna et al (5) nearly 1400 
Penicillium isolates were collected from several cultures, 
isolated directly from food and feed. Each isolate was identi-
fied using Pitt's classification to investigate their mycotoxins 
production, and 18 different mycotoxins were isolated. Each 
isolate was allowed to grow on malt extract agar medium 
and was incubated for the period between one to three 
weeks at 25˚C. The mycotoxins were then extracted using 
chloroform and filtration, and the produced mycotoxins 
were concentrated. Finally, the mycotoxins were classified 
and characterized by mycotoxins analysis using TLC (6-8). 
This experiment resulted in the production and the identifi-
cation of 18 different mycotoxins from one or more species 
of Penicillium. The toxins are as follows: Brevianamid A 
produced by 3 species, Citreoviridin produced by 2 species, 
Citrinin (fig. 2) produced by 3 species, Cyclopiazonic acid 
produced by 8 species, Fumitremorgin B produced by 1 
species, Griseofulvin produced by 6 species, luteoskyrin 
produced by 1 species, Ochratoxin A produced by 2 species, 
Patulin produced by 4 species, Penicillic acid produced by 2 
species, Penitrem A produced by 1 species, PR-toxin produced 
by 1 species, Roquefortine produced by 2 species, rugulosin 
produced by 2 species, verrucosidin produced by 1 species, 
verruculogen produced by 1 species, viridicarumtoxin 
produced by produced by 2 species and finally, Xanthomegnin 
produced by 2 species (5).
Another group of mycotoxins is produced by Aspergillus 
species, and these mycotoxins are called Aflatoxins (12). 
They were found to be extremely toxic and highly cariogenic. 
Aflatoxins are chemical compounds that are released by 
the fungi Asergillus Flavus and Aspergillus Parasiticus as 
secondary metabolites, and the different laboratory investi-
gations confirmed the high carcinogenicity of these chemical 
compounds and how they are associated with many cancers 
such as liver and kidney (9-12). The different types of afla-
toxins include aflatoxin B1 and B2, produced by Aspergillus 
Flavus and Aspergillus parasiticus, Aflatoxin G1 and G2, 
produced by Aspergillus parasiticus (13-16). Among these 
toxins, it was found the B1 and G1 are the most toxic with the 
highest carcinogenic effect on animal cells (9). Food products 
that can be contaminated with aflatoxins include cereal (maize, 
sorghum, pearl millet, rice, and wheat), oil seeds (groundnut, 
soybean, sunflower, and cotton), spices (chilies, black pepper, 
coriander, turmeric, and ginger), tree nuts (almonds, pistachio, 
walnuts, and coconut) and milk (17-22). Moreover, aflatoxins 
are found in the contaminated tobacco leaves (23). Aflatoxins 
can also be present in the dry soil, which can move through 
underground water with rain and be ingested by humans and 
animals through drinking water (24).
Another group of mycotoxins that is produced by 
Aspergillus, Penicillium and Fusarium were classified and 
characterized based on the frequency of their accordance with 
nature and their severity of the diseases they cause. These 
mycotoxins are Deoxynivalenol (Fig. 8), Fumonisins (Fig. 4), 
Zearalenone (Fig. 10), T-2 toxin (Fig. 7), and finally certain 
types of ergot alkaloids. Found mainly on grain crops (29-31), 
they were known to develop a set of diseases called Myco-
toxicoses, and these diseases include blood toxicity, food 
poisoning and sometimes cancer (25-27).
Figure 1. Chemical structure of Aflatoxin B1.
figure 2. Chemical structure of Citrinin.
figure 3. Chemical structure of Ergotamine.
ONCOLOGY REPORTS  37:  1321-1336,  2017 1323
Another group of mycotoxins is produced by the Fusarium 
species and when culturing the Fusarium moniliforme 
cultures on corn, a mycotoxin called fumonisins was found 
to be produced (28). When analyzing fumonisins using liquid 
chromatography, three types of fumonisins were found namely 
B1 (fB1), B2 (fB2), and B3 (fB3) and all three types are 
isolated when allowing the fusarium to grow on corn and the 
concentrations of fumonisins will range from 800-12800 ng 
total fumonisins/g (29).
In addition to the aflatoxins, another group of mycotoxins 
were found to have a similar action on humans and animals, 
grouped as the Ochratoxins (30-32). The Ochratoxins are 
mycotoxins produced by some Aspergillus species such as 
A. Ochraceus and A. Niger, whereas some Penicillium species 
such as P. Verrucosum and P. Carbonarius are also found to 
produce Ochratoxins (32). Among all the types mentioned, 
Ochratoxin A is the most common and it has the highest 
degree of toxicity (33-35). The Ochratoxins can be found in 
cereals, coffee, dried fruit, and red wine. It can be accumulated 
in the meat of animals and thus, meat and meat products can 
be contaminated with this toxin (36-39).
As previous literature indicates, fungal strains can be 
found in many terrestrial habitats which make the availability 
of different mycotoxins a very common phenomenon. Since 
many different fungal strains such as Penicillium, Aspergillus 
and Fusarium species grow very well on commodities such 
as crops, grains and stored animal feed, the chances of myco-
toxins entering the humans or animal biological system are 
very high, mostly accompanied with many health concerns 
and medical complications (40).
3. The chemical and physical nature of mycotoxins
Researched confirmed that the most important mycotoxins 
are Citrine, Aflatoxin B1, Ergot, fumonisins akaloids, Patulin, 
Trichothecene, Zearalenone and Ochratoxin A and the reason 
behind their importance is the fact that they are involved in 
many human and animal diseases which sometimes leads to 
death (41).
Aflatoxin B1. Aflatoxins are the most important myco-
toxins that are produced mainly by Aspergillus Flavus and 
Aspergillus Parasiticus (42), and they are mainly produced 
by the aspergillus species (43-45). There are four types of 
aflatoxins named B1, B2, G1, and G2 and can be categorized 
based on two characteristics: Their fluorescence color under 
uv light (whether it is blue or green), and their mobility 
during TLC (41). The chemical formula of the aflatoxin is 
C17h12O6 (Fig. 1) (46). The biosynthesis of aflatoxins starts 
with the production of norsolorinic acid which is an anthraqui-
none precursor joined together by the action of the enzyme II 
polyketide synthase followed by 15 post-polyketide synthase 
steps which will yield a series of toxigenic metabolites (47-52).
Citrinin. Chemically, citrine is known as (3R,4S)-8-
hydroxy-3,4,5-trimethyl-6-oxo-4,6-dihydro-3h-isochromene-
7-carboxylic acid (53) and its chemical formula is C13h14O5 
(fig. 2) (54). It is mainly produced by Penicillium Citrinum (55). 
Citrinin is connected to the yellow rice disease in Japan and it 
is a potent nephrotoxin in animals. Its acute toxicity varies with 
different species (56,57).
Ergot alkaloids. The most important and fascinating Ergot 
alkaloids is the Ergotamine, produced mainly by Claviceps 
Sclerotia and its chemical formula is C13h14O5 (Fig. 3) (58). 
Ergotamine is made up of indole alkaloids that are derived 
from a tetracyclic ergoline ring system (59).
Fumonisins. The most important fumonisins are the 
fumonisin B1 and they are the product of condensation of 
alanine into acetate-derived precursor (60). The chemical 
formula of the fumonisin B1 is C34h59NO15 (fig. 4) and it is 
basically produced by the fusarium species (61).
Ochratoxins. The most important ochratoxin is the 
Ochratoxin A, which is produced mainly by Aspergillus 
Ochraceus (62) and its chemical formula is C20h18ClNO6 
(fig. 5) (63).
Patulin. This mycotoxin is produced by the Penicillium 
pabulum, and its chemical name is 4-hydroxy-4h-furo[3,2c] 
pyran-2(6h)-one (64). The chemical formula is C7h6O4 
(fig. 6) (65). This toxin was once used as an antibiotic until 
it was proven toxic in the 1960s and classified as a myco-
toxin (64).
Trichothecenes. This group of mycotoxin contains three 
major toxins called T-2 toxin (Fig. 7), Deoxynivalenol (Fig. 8) 
and Satratoxin H (Fig. 9) and they are produced mainly 
by Myrothecium, Phomopsis, Trichothecium, Fusarium, 
Trichoderma and Stachybotrys (66-68). Chemically, trichot-
figure 4. Chemical structure of fumonisin B1.
figure 5. Chemical structure of Ochratoxin A.
figure 6. Chemical structure of Patulin.
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hecenes are made up of 12, 13-epoxytrichothene skeletons 
linked up with an olefinic bond with various side chain 
substitutions. Trichothecenes can be classified into group A, 
which has hydrogen or ester type side chain at the C-8 posi-
tion and include T-2 toxin, and group B which has a ketone 
and include fusarenon-x, nivalenol, and deoxynivalenol (69). 
Satratoxin is another important Trichothecene which is a 
macrocyclic trichothecene produced mainly by Stachybotrys 
Atra. Research has proven its toxicity towards humans and 
animals (70).
Zearalenone. This mycotoxin is mainly produced by 
fusarium Graminearum and its chemical name is 6-[10-hydroxy-
6-oxo-trans-1-undecenyl]-B-resorcyclic acid lactone (71). The 
chemical formula of Zearalenone is C18h22O5 (fig. 10) (72).
Mycotoxin chemical composition makes them strong and 
stable to a point where they cannot be completely destroyed 
during the different food processing procedures. They can 
contaminate the final food product which will eventually 
enter the humans biological system (73). When the food that 
is processed is mainly cereals, the contaminating myco-
toxins most likely to be found are Aflatoxins, Ochratoxin A, 
fumonisins, Deoxynivalenol and Zearalenone (74). 
Mycotoxins can be affected by different food processes such 
as trimming, cooking, baking, cleaning, canning, alkaline 
cooking, frying, roasting, flaking, nixtamalization, sorting, 
milling, extrusion and brewing (75). With the increase in the 
temperature, the effect on the mycotoxin will increase but due 
to its chemical nature, the concentration of the mycotoxins will 
be reduced. Despite this, mycotoxins cannot be completely 
eliminated (73). High temperature that is greater than 150˚C 
during the extrusion was needed to reduce zearalenone greatly 
and aflatoxins moderately (76). In the same temperature during 
the extrusion process, there will be a low reduction of deoxyni-
valenol and a high reduction of fumonisins. Temperatures 
160˚C and higher with the addition of glucose was found to 
reduce fumonisin to even greater levels (73).
In another experiment, the degradation of aflatoxin 
was examined in different conditions and it was found that 
Aflatoxin can be partially or completely degraded by several 
sterilization techniques such as heat and irradiation. Besides 
that, aflatoxins can be eliminated by the addition of bisulfate, 
strong acids, strong bases or oxidizing agent or treatment with 
strong acids or bases, oxidizing agents or bisulfite. Hydrogen 
peroxide plus riboflavin denature aflatoxin in milk (77). 
Chemical stability of Nivalenol, Deoxynivalenol and 
Zearalenone related to moisture, ph and heat was studied by 
Lauren and Smith (78) and the results showed that Nivalenol 
and deoxynivalenol are stable in buffer solutions that have 
the range of Ph 1-10, but with a Ph higher than 12, high salt 
concentration and a temperature of 80˚C for a long period of 
time, both Nivalenol and deoxynivalenol tend to break down. 
In the same experiment, both Nivalenol and deoxynivalenol 
are reduced to 60-100% by treating the contaminated food 
with 10, 20 or 50% of the food dry weight with bicarbonate 
solution and raise the temperature up to 80 or 110˚C for 
2-12 days. finally, in the case of zearalenone, the result shows 
that it is highly stable and cannot be broken down even when 
Figure 8. Chemical structure of Deoxynivalenol.
figure 7. Chemical structure of T-2 toxin.
Figure 9. Chemical structure of Satratoxin H.
figure 10. Chemical structure of Zearalenone.
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treated with sodium bicarbonate solution at a temperature of 
110˚C for more than 12 days (78).
All mycotoxins have at least one benzene ring which gives 
them thermodynamic and chemical stability, and that is mainly 
why they require a high temperature to desaturate and to be 
utilized as less complex compounds (27,54,60,62,65,66,72,79,80). 
This stability makes mycotoxins highly resistant when it comes 
to decontamination and sterilization and that in turn will 
increase the chances of contaminating human food and animal 
feed (55,72,73,81). Finally, the chemical and physical nature of 
mycotoxins makes them a very strong carcinogenic agent that 
can be related to different cancer types in all countries around 
the world.
4. The action of mycotoxins on the cellular genome and its 
effect on humans
The most dangerous mycotoxins are the aflatoxin B1 (Fig. 1) 
and Ochratoxin A (fig. 5) for their lethal effect on humans and 
animal. Aflatoxin B1 has the highest carcinogenicity among all 
mycotoxins and it is capable of penetrating the cell membrane 
and attach to its DNA where it makes changes to the genome in 
order to become more stable (2,82,83). Aflatoxin B1 is consid-
ered a liposoluble compound which can be absorbed from the 
site of exposure and move into the blood stream throughout 
the body (84). As soon as the aflatoxins enter the cells, they get 
metabolized by cytochrome P450, to aflatoxin-8, 9-epoxide 
which is highly reactive and unstable and requires the binding 
to a DNA or to the protein molecule in order to become more 
stable (85,86). Once the highly unstable aflatoxin-8, 9-epoxide 
binds to the DNA molecule with high affinity, it forms 
aflatoxin-N7-guanine that causes GC to TA transversion muta-
tions. This will directly affect the cell cycle by affecting the 
P53 gene which encodes tumor suppressor protein that inhibits 
the development of tumors and cancers (87,88).
Ochratoxin (fig. 5) is another mycotoxin which is given a 
similar importance as Aflatoxin B1 because of how it targets 
the kidney (89). Ochratoxin A is considered a nephrotoxin to 
animals and humans and is a very strong liver toxin, potent 
teratogen, carcinogenic and immune suppressant (90,91). 
Ochratoxin A will mainly disturb cellular physiology 
in several ways, but the primary effects of it are usually 
associated with the enzymes that are involved in phenyl-
alanine metabolism which inhibits the enzyme involved in 
the synthesis of the phenylalanine-tRNA complex (92,93). 
Moreover, Ochratoxin A is capable of inhibiting mitochondrial 
ATP production and is considered a strong stimulant for lipid 
peroxidation (35,94).
Trichothecene mycotoxins are proven to have multiple 
inhibition effects on eukaryote cells where they inhibit 
protein, DNA and RNA synthesis, mitochondrial function 
and effects both cell division and cell membrane of the 
eukaryotic cells (95). Trichothecenes are capable of inducing 
a programmed cell death response within infected cells, 
causing a reduction in downstream gene products, starting a 
ribotoxic stress response and activating a mitogen-activated 
protein kinase (96). Deoxynivalenol mycotoxin (Fig. 8) 
usually mediates an inflammatory response by controlling 
the binding activities of some transcription factors which 
will results in inducing cytokine gene expression (97). In 
animal cells, Trichothecenes are capable of inhibiting protein 
synthesis, inhibiting RNA and DNA synthesis; altering cellular 
membrane structure, interfere with mitochondria functions, 
initiating apoptosis, activation of MAPK and finally, activation 
of the cytokine (98-104).
Citrinin (fig. 2) is considered as one of the strongest neph-
rotoxins to animals, and the levels of toxicity differ between 
species (56). Citrinin can act together with Ochratoxin A, 
interfere with RNA synthesis and suppress it in rodent 
kidneys (105). Citrinin is known to inhibit cytokine expression 
and reduce the interleukin-4 in T-helper type 1 which would 
result in increasing the risk of allergies in humans (106). It is 
considered genotoxic at high concentrations to cultured human 
lymphocytes (107). finally, Citrinin is considered a nephro-
toxin which causes nephropathy and impose oxidative stress, or 
increase the permeability of mitochondrial membranes (108). 
Ergot Alkaloids mycotoxins are a type of Citrinin, and they are 
known to induce humans ergotism, low nerve fever in humans 
and have a strong influence on fertility (109-111). Although 
certain cleaning processes for grains has overcome the problem 
of ergotism, it is still considered a significant animal problem 
which causes symptoms such as abortion, suppression of 
lactation, hypersensitivity, ataxia and gangrene (112,113) and 
smooth muscle contractions (114). Despite its toxicity, Ergot 
Alkaloids mycotoxins and its derivatives are used widely in 
abortifacient and as a drug to accelerate uterine contractions 
during labor (114). They are also used for the treatment of 
migraine headaches, prolactin inhibitors for the treatment of 
Parkinsonism and for the treatment of cerebrovascular insuf-
ficiency (59). Unfortunately, the use of ergot alkaloids may 
result in the development of human ergotism (115).
fumonisin B1 (fig. 4) is an important fumonisins myco-
toxin which was reported to be a hepatotoxic and carcinogenic 
toxin (28,116,117). In addition, fumonisin B1 was reported 
to cause apoptosis in the liver of rats (118) and there is a 
possibility that it can be linked to esophageal cancer (119). 
FB1's main action is to disrupt sphingolipid metabolism 
which induces lipid peroxidation that will end up altering 
the cell membrane, causing cell death through apoptosis. It 
also has the potential of inhibiting protein synthesis and in 
higher concentration to inhibit DNA synthesis (120). It was 
proven to have some carcinogenic activity by stimulating 
3h thymidine incorporation (121). fumonisin mycotoxins 
are involved in the neural tube defects in animals, and it was 
hypothesized that it can have the same effect on humans. A 
cluster of anencephaly and spina bifida cases in Texas in the 
uSA is related to fumonisins mycotoxins infection in corn 
products (122,123) and it was evaluated by the International 
Agency for Research that fumonisins have a cancer risk to 
humans. Its carcinogenicity is classified as group 2B which 
means probably carcinogenic (124). Another mycotoxin that 
affects humans on a cellular level is Patulin (fig. 6) which is 
just as toxic at high concentration in but there is not enough 
evidence for natural poisoning, and its recorded poisonous 
effects are inconclusive (125).
Trichothecene mycotoxins were proven to be extremely 
potent inhibitors of eukaryotic protein synthesis, and were 
found to interfere with initiation, elongation, and termination 
stages of protein synthesis. They are the first mycotoxin from 
the trichothecene group known to inhibit peptidyl transferase 
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activity during protein synthesis (126,127). The way trichot-
hecenes inhibit peptidyl transferase is by binding to the same 
ribosome-binding site, leading to correlation with different 
functional groups and subsequently affecting the protein 
synthesis process (128). Among all Trichothecene mycotoxins, 
Deoxynivalenol is the most commonly found mycotoxin in 
different grains and once they are ingested, are reported to 
cause nausea, vomiting, and diarrhea with refusal for food 
and weight loss in animals (129). Deoxynivalenol was found 
to have a mitogen-activated protein kinase-mediated IL-8 
expression in cloned human monocytes and peripheral blood 
mononuclear cells where the concentration of deoxyniva-
lenol is from 250 to 1000 ng/ml. This will induce both IL-8 
mRNA and IL-8 heteronuclear RNA which is an indicator of 
IL-8 transcription in human U937 monocytic cell line in a 
concentration-dependent manner (130).
Other Trichothecene mycotoxins that were found to have a 
great toxic effect on humans and animals are T-2 (fig. 7) and 
diacetoxyscirpenol. Both were proven to be immuno suppressive 
in which they reduce resistance towards different infections 
and microbes (129,131). T-2 mycotoxin was proven to induce 
apoptosis at 10 ng/ml concentration (132) and was reported to 
inhibit the platelet aggregation and the release of dense bodies 
with a change in the membrane permeability (133). On the 
other hand, diacetoxyscirpenol is capable of inhibiting protein 
synthesis, has high immunomodulatory effects (134) and was 
reported to cause alimentary intoxication, food poisoning and 
induce hematological symptoms (135). Moreover, it was proven 
that T-2 and diacetoxyscirpenol are capable of causing several 
dermatological, gastrointestinal, and neurologic symptoms in 
humans and animals (136). finally, T-2 and diacetoxyscirpenol 
are hypothesized to be associated with a humans disease called 
alimentary toxic aleukia in which the infected person will have 
skin inflammation, continuous vomiting, and damage to hema-
topoietic tissues that gives rise to blood cells and in advanced 
stages, cause central nervous system disorders, oral cavity, and 
severe bleeding from the nose, mouth, and vagina (111).
Zearalenone mycotoxins (f-2) (fig. 10) are a unique 
mycotoxin that is biologically potent but is hardly toxic and 
resembles 17β-estradiol, which is an ovary hormone which 
humans produce to help the ovaries bind to estrogen receptors 
in the target cells. Therefore, it can be classified as a non-
steroidal estrogen or mycoestroge (137) and used to reduce the 
postmenopausal symptoms in women (138). The major effects 
of Zearalenone are on the reproduction in females, where it 
affects reproductive organs and their function, eventually 
leading to a medical condition called hyperestrogenism (137). 
Zearalenone in its reduced form, zearalenol, is known to 
increase estrogenic activity (139) but it was proven to cause 
disrupted conception, abortion, and other problems in female 
pigs (140) and that can be hypothesized for humans as well.
5. Mycotoxins and their carcinogenicity
The effects of mycotoxins on humans and animals will 
vary based on the nature of the toxins. While several are 
considered to be mutagenic; it was proven that Aflatoxin B1, 
Ochratoxin A and Sterigmatocystin are strong carcino-
gens (17). In a study made to identify the DNA-attacking 
ability of carcinogenic mycotoxins, six Penicillium toxins 
that include patulin, Citrinin, penicillic acid negative-
luteoskyrin, positive-rugulosin, and PR-toxin, 5 aspergillus 
toxins including O-acetylsterigmatocystin, sterigmato-
cystin, O-acetyldihydrosterigmatocystin aflatoxin B1 and 
aflatoxin G1, and two fusarium toxins that include zeara-
lenol-b and zearalenone, all these mycotoxins were found 
to have destructive ability towards genomic DNA (141). 
Although these 13 mycotoxins have the ability to attack 
the genomic DNA, 8 of them were found to be highly 
carcinogenic, including penicillic acid, citrinin, patulin, 
negative-luteoskyrin, positive-rugulosin, sterigmatocystin, 
aflatoxins B1, and G1 (141).
In another experiment conducted on mice, the effect of 
luteoskyrin and cyclochlorotine mycotoxins was investigated, 
and it was found that both toxins have hepatotoxic and hepa-
tocarcinogenic activities on rats (142) with a hypothetical 
possibility to affect humans in a similar fashion. fumonisin 
mycotoxins were found to be carcinogenic in rats due to their 
action in inhibiting ceramide synthase in vitro which in turn 
would enhance the production of tumor necrosis factor α 
(TNfα). This leads to the initiation of cells apoptosis (143). In 
addition, an experiment was conducted using 28 mycotoxins 
to investigate their action against hepatocytes of rats and mice. 
The results of the experiment showed that unknown carci-
nogenic mycotoxins such as 5,6-dimethoxysterigmatocystin, 
versicolorins A and B, averufin, xanthomegnin, luteosporin, 
and chrysazin, known carcinogenic mycotoxins such as afla-
toxin B1 (fig. 1), sterigmatocystin, luteoskyrin, Ochratoxin A 
(fig. 5), azaserine, mitomycin C, and actinomycin D have 
the tendency to elicit DNA repair synthesis, which suggest 
the possibility of these mycotoxins to be genotoxic carcino-
gens (144). On the other hand, some carcinogenic mycotoxins 
such as penicillic acid, patulin, griseofulvin, and rugulosin 
were not found to elicit DNA repair synthesis and suggest the 
possibility of these mycotoxins being nongenotoxic carcino-
gens (144).
Aflatoxin B1. Aflatoxin B1 has a ubiquitous nature and is 
considered a toxic metabolite, making it a serious public health 
concern. Furthermore, aflatoxin B1 (Fig. 1) toxin contamination 
is related to liver diseases (145). Aflatoxin B1 is said to have an 
active role in causing hepatic and extrahepatic carcinogenesis 
in both humans and animals by inducing a DNA single strand 
break (146) and through bio activation of Aflatoxin B1 to its 
epoxide metabolite. As a result, it will interact with the DNA 
molecule which will finally lead to neoplastic transformation of 
the cells (147). The activation of Aflatoxin B1 is accomplished 
by two approaches, chemical and enzymatic in which the 
Aflatoxin B1 will be biologically active. The chemical activa-
tion of the Aflatoxin B1 will be through the chemical oxidation 
of dimethyldioxirane whereas the enzymatic activation will be 
through the cytochrome P450. Combined, they are a mixed-
function oxidase that will give rise to a mixture of exo and 
endo-8, 9-epoxides (148). The exo-8, 9-epoxides will interact 
with the DNA molecule by attacking the nitrogen atom at the 
7 position (N7) of guanine at the C8 of the epoxide by the Sn2 
reaction. This process initiates the trans adduct that will lead 
to the development of a malignant cell. They are considered to 
be carcinogenic agents (149,150). On the other hand, it is not 
capable of interacting with DNA molecules. hence, it is not 
considered a carcinogenic agent (148).
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It was reported that almost half of the hepatocellular 
carcinomas (hCC) were reported in the part of the world 
that witnessed high levels of Aflatoxin B1 contamination in 
food where a mutation in the 249th codon of the P53 tumor 
suppressing gene (151). The mutation caused in this codon 
is in the form of transversion in the third position of this 
codon and will cause the insertion of serine at the 249 in the 
mutant protein (152). In addition to the G-->T transversion, 
Aflatoxin B1 will cause G-->T and C-->A transversions into 
adjacent codons but with reduced frequency but it was proven 
only as G-->T transversion at 249 codon. It turns out that the 
mutant serine 249 p53 protein are responsible for the muta-
tion at p53 in HCC from aflatoxin B1 in the areas that were 
reported to have aflatoxin B1 contamination in the food (153). 
This confirmed that aflatoxin B1 is hepatocarcinogenic (154). 
In another study, there was an increase of the hepatocellular 
carcinoma in Mozambique and Transkei, and several parts 
of Asia (155) including China (156) and Africa including 
Kenya (153).
Inhalation of aflatoxin B1 is thought to cause primary 
lung cancer due to the activation of it to its biologically 
active form 8, 9-epoxide where the rate of 8, 9-epoxide was 
measured using AfB1-glutathione (AfB1-GSh) conjugate by 
HPLC with aflatoxin b1 at a concentration of 124 µm. Rates 
of activation were less than in the liver cells most probably 
due to the CYP-containing cells that are less abundant in the 
lungs than in the liver (157). In another study, the x-ray cross-
complementing group 1 protein (xRCC1) which is involved 
in the repair mechanism of the single strand DNA was inves-
tigated in the presence of aflatoxin. A substitution of guanine 
to adenine was found at codon 399 and that in turn was found 
to increase the risks of adenocarcinoma of the lung (158). The 
presence of aflatoxin B1 has been confirmed in two cases 
of human lung cancer using thin-layer chromatography and 
fluorescence microscopy (159,160). Finally, the expression of 
GSTM1-1 that is responsible for the production of cytosolic 
Glutathione S-transferases helps in detoxifying several carci-
nogenic electrophiles in the presence of polycyclic aromatic 
hydrocarbons that serves as the main compound, yielding 
substrates for these enzymes, and naturally was affected by 
the presence of Aflatoxin B1, which leads to inactivation of 
GSTM1-1 and increased risk factor for lung cancer (161).
Ochratoxin A. Ochratoxin A (fig. 5) was reported to be 
associated with different effects on humans and animals but 
their nephrocarcinogenicity was found to be the most impor-
tant effect, and that made it a major public health concern. 
In an experiment conducted on male fischer rats that were 
fed Ochratoxin B1, a renal tumor was discovered within the 
first six months, and the tumor incidents increased by 25%. 
This is because the genes responsible for kidney injury and 
cell regeneration were significantly influenced by the action 
of Ochratoxin A (162). Ochratoxin A was found to cause an 
alteration of gene expression that resulted in affecting calcium 
homeostasis which disrupts the different pathways regulated 
by the hNf4α and Nrf2 in the kidney (163). In addition, 
Ochratoxin A was found to have a small influence on the 
expression of genes involved in DNA synthesis and repair and 
ones induced as a result of DNA damage. There was minimal 
to no influence at all on the genes that are responsible for 
apoptosis (163,164). Ochratoxin was also found to effect Nrf2-
regulated genes in the kidney that is required for the chemical 
detoxication and antioxidant defense within the cell. That in 
turn affects the cell's defense mechanism while also causing 
an increase in the kidney oxidative stress, which contributes to 
the Ochratoxin A carcinogenic nature (165). Ochratoxin A is 
suggested to have a renal carcinogenesis effect on the kidneys 
and its mode of action is by the means of direct genotoxicity 
through covalent DNA adduct formation. This information 
should be taken into consideration for Ochratoxin A for OTA 
human risk assessment (166).
The alteration caused by Ochratoxin A could lead to 
single cell death in kidney and stimulates cell proliferation 
and an enlarged cellular nucleus which indicates blocked 
nuclear division during mitosis. Exposure to Ochratoxin A 
could also lead to overexpression of mitosis regulators such 
as mitotic protein kinases Polo-like kinase 1, Aurora B and 
cyclin-dependent kinase 1, cyclins and cyclin-dependent 
kinase inhibitors, topoisomerase II and surviving (167). 
Ochratoxin A (Fig. 5) is classified as a ubiquitous nephrotoxic 
mycotoxin and it was reported to be responsible for human 
Balkan endemic nephropathy and involved in urinary tract 
tumors. For this reason, it was classified by the Agency for 
Research on Cancer as a possible carcinogen belonging to 
group 2B (168). Ochratoxin A has a genotoxic activity on the 
cell DNA followed by oxidative metabolism, which plays a 
major role in Ochratoxin mediated carcinogenesis. It can be 
divided into direct modes of action where Ochratoxin A is 
involved in covalent DNA adduction and indirect modes where 
Ochratoxin A is involved in oxidative DNA damage (169). 
Ochratoxin OTA is a genotoxic carcinogen because of their 
ability to oxidase DNA lesions and the direct DNA adducts 
through quinone formation (170). Ochratoxin A was proven 
to increase phosphorylation of atypical-PKC which in turn 
leads to a downstream activation of ERK1 and ERK 2 and 
their substrate ELK1, ELK2 and p90RSK where PKC and 
the MEK-ERK MAP-kinase pathways are activated by 
Ochratoxin A involved in cell proliferation, cell survival, 
anti-apoptotic activity and most importantly renal cancer 
development (171).
A study on rodents supported the involvement of 
Ochratoxin A mycotoxin in developing breast cancer through 
genetic damage, and the study hypothesized the possibility 
of the Ochratoxin A in causing breast cancer. The validity of 
that hypothesis relates to data that show an increase in breast 
cancer cases when a number of people in a population migrate 
from one geographic area to another (172). Ochratoxin A was 
hypothesized to be involved in testicular cancer which is one 
the most common cancer affecting young men due to adducts 
in testicular DNA where the consumption of Ochratoxin 
during pregnancy and during young childhood would cause 
lesions in the testicular DNA during puberty. These lesions 
will develop into testicular cancer (173-175).
Citrinin. Citrinin (fig. 2) is considered as nephrotoxic 
mycotoxin (176), and traces of Citrinin were found in contami-
nated food in areas known to have endemic nephropathy, 
diseases that are associated with urinary tract cancer. It 
produced micronuclei and DNA migration and had the poten-
tial of inducing micronuclei in hepG2 (human-derived liver 
cell line), and can cause DNA damage, effectively increasing 
the risk of cancer in humans (177). Citrinin was proved to 
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induce chromosomal aberrations in both humans and rat liver 
microsomes. In addition, Citrinin can also cause complex 
translocations with the cellular DNA in a high frequency, and 
is capable of inducing defects in chromosomal coiling (178), 
which may lead to the formation of DNA adducts (179). In 
an experiment performed to assess the effect of Citrinin on 
viability and DNA fragmentation and chromosome aberrations 
in mouse bone marrow cells and cultured vero cells, Citrinin 
was found to be a weak cytotoxic. however, it causes DNA 
fragmentation and chromosome aberrations that may lead to 
cancer, apoptosis, and carcinogenesis (180). Citrinin was found 
to inhibit cell-free microtubule polymerization and it has an 
aneuploidogenic activity. Citrinin is also a source of mitotic 
arrest and CREST-positive micronuclei where it will induce 
the formation of micronuclei containing whole chromosomes 
or chromatids (181). Finally, some strong evidence suggests 
that Citrinin is involved in the development of Balkan endemic 
nephropathy and associated urinary tract tumors (182).
Fumonisins. fumonisin (fig. 4) is a potential cancer 
causing agent in humans (183). An experiment was conducted 
on 25 rats where their food was mixed with fumonisin B1 
for a period ranged from 6 to 26 months and the result of the 
experiment confirmed that Fumonisin B1 is hepatocarcino-
genic and hepatotoxic (184,185). Fumonisins are capable of 
inhibiting the biosynthesis of sphingosine and the complex 
sphingolipids by inhibiting the enzyme ceramide synthase and 
that, in turn, will lead to the increase of free sphinganine and 
the free sphingoid bases which are toxic to cells. In cultured 
cells that are treated with fumonisin B1, the accumulation of 
bioactive long-chain sphingoid bases and depletion of complex 
sphingolipids essential for cell growth and development lead 
to inhibiting the growth, increasing cell death, and influence 
on mitogenicity that would lead to the development of cancer 
in fibroblast cell line 3T3 (186).
fumonisins were found correlated with incidence of 
esophageal cancer in both Southern and Northern Africa and 
China, neurodegenerative disease (187,188) and leukoencepha-
lomalacia in horses (28). It was proven that fumonisin B1 are 
involved in the development of renal carcinomas in male rats, 
and liver cancer in female mice which could occur in humans 
as well (189). Finally, Fumonisin B1 was found to cause inhibi-
tion in the production of ceramide synthase in vitro which in 
turn enhances tumor necrosis factor α, production and cause 
apoptosis (143). finally, fumonisins mycotoxins were found 
to contribute to the development of neural tube defects among 
Mexican-American woman in south Texas, and was character-
ized by defects in the brain, spine, or spinal cord of fetus in the 
first month of pregnancy (190).
Patulin. Patulin (fig. 6) and its precursor 6-methylsali-
cylic acid are derived from Acetyl-CoA which makes them 
polyketides and carcinogenic mycotoxins (191,192). They are 
capable of causing gene mutations in different mammalian 
cells (193). The administration of patulin subcutaneously 
twice a week for 15 months showed the development of malig-
nant tumor cells in the area of administration which proved the 
carcinogenic effect of this mycotoxin. It can by hypothesized in 
humans as well (64,194-196) although the carcinogenic effect 
of patulin was not confirmed by Osswald at al (197), patulin 
was confirmed to be toxic to the mice born to patulin treated 
mothers and deaths occurred in both males and females. 
Patulin is found to be mutagenic, carcinogenic and teratogenic 
and it has the tendency to induce intestinal injuries (198) and 
it has the ability to attack cellular DNA in bacteria (199) and 
humans (141), that can lead to the development of tumors, and 
cancer.
It was proposed that the toxicity of patulin for intestinal 
cells involves an inactivation of the active site of protein 
tyrosine phosphatase (PTP). The protein tyrosine phosphatase 
is a key regulator of intestinal epithelial barrier function, and 
the active site of PTP contains a cysteine residue (Cys215) 
which is important and required for phosphatase activity. On 
the other hand, the sulfhydryl-reacting compounds such as 
acetaldehyde decrease the transepithelial resistance (TER) 
through a covalent modification of cysteine residue Cys215 
of the protein tyrosine phosphatase and this toxicity can lead 
to damage in the intestinal cells that eventually may lead to 
intestinal and stomach cancer (198) and this evidence can be 
used to hypothesize and indicate the involvement of patulin in 
the development of intestinal and stomach cancer in humans. 
Patulin was found to inhibited the cell-free microtubule 
polymerization, it has the ability to bind covalently to reac-
tive thiol groups of microtubule proteins, and deactivates the 
protein. It induces the formation of micronuclei that contains 
the whole chromosomes or chromatids, it also induces the 
formation of micronuclei containing acentric chromosomal 
fragments, and that indicates its clastogenic ability, and finally, 
Patulin has both aneuploidogenic and clastogenic properties 
that could contribute to the carcinogenicity of this mycotoxin 
in the long-term studies which in turn could be hypothesized 
in humans as well (181).
Trichothecenes. T-2 (fig. 7) are mycotoxins that belong 
to Trichothecene mycotoxin and is considered as immuno-
suppressive, cytotoxic and lymphocytic and carcinogenic 
mycotoxin in mammalian cells (17) although the work of 
ueno et al (200) on Salmonella typhimurium suggested that 
trichothecenes have failed to demonstrate mutagenicity. T-2 is 
capable of inducing breaks in the DNA of lymphocytes when 
administrated in vivo and in vitro and once fibroblast cells are 
treated with this mycotoxin incorporation with 3h thymidine, 
unscheduled DNA synthesis will take place (201). The suscep-
tibility of newborn and immature animals to T-2 are more 
compared to adults and it causes a high degree of edema and 
dermal toxicities through the direct attack of trichothecenes 
on the capillary vessels (202). In the presence of aflatoxin B1 
(Fig. 1), the trichothecenes nivalenol, will enhance the afla-
toxin B1-induced hepatocarcinogenesis and T-2 lack any 
hepatocarcinogenesis ability and that was confirmed by an 
investigation in the presence of GST-P-positive foci that acts 
as a marker for the presence of hepatocarcinogenesis (203). 
Although it was proposed (204) that under the experimental 
conditions in both in vivo and in vitro, no damage took place 
in the hepatic DNA, T-2 has the ability to decrease responses 
to mitogens in human lymphocytes in vitro (205).
The exposure to trichothecene mycotoxin can activate 
apoptosis in both in vitro and in vivo within many organs 
that include the lymphoid organs, the hematopoietic tissues, 
with in the liver and the intestine, in the bone marrow and 
finally the thymus (95,206,207) and it inhibits the protein 
synthesis (206,208) and it was found to induce cellular 
necrosis and karyorrhexis in the dividing tissues of the intes-
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tinal mucosa, bone marrow, spleen, testis, and finally, the 
ovary (208).
Another trichothecene mycotoxin that has the ability to 
increase the frequency of inducing mutation and cancer is 
Nivalenol. Nivalenol can also be involved in casing sister chro-
matid exchange in Chinese hamster cells and it can case DNA 
damage making it a potential genotoxic agent (205) which can 
be hypothesized in humans as well. Nivalenol acute toxicity 
can lead to bone marrow toxicity and Nivalenol chronic 
toxicity would lead to leucopenia (209). Unfortunately, there is 
no clear evidence of Nivalenol carcinogenicity in experimental 
animals or humans and an investigation was carried on cell 
lines in vitro (205,210).
Diacetoxyscirpenol mycotoxin is another group of 
trichothecene mycotoxin which is known to inhibit the prolif-
eration and Ig production in the mitogen-stimulated human 
lymphocytes (211) and it causes esophageal hyperplasia but 
is not capable of inducing cancer in rats (212) and despite its 
toxicity, it was used as a chemotherapeutic agent for cancer 
treatment (132).
finally, fuS-x in another group of trichothecene myco-
toxin which is capable of causing an immunosuppressive 
response, carcinogenicity, cytotoxicity in experimental 
animals and possibly in humans as well (208). FUS-X is toxic to 
many cell types such as murine thymocytes, lymphocytes, and 
gastric epithelial cells but they have a high degree of toxicity 
to human hepatoblastoma cells (213). It can initiate apoptosis 
in mouse thymocytes in vivo as well as in vitro (214,215) that 
can be hypothesized in humans as well. Although fuS-x 
was confirmed to be carcinogenic in animals (208), no clear 
evidence is available on its carcinogenicity in humans (213). 
fuS-x is highly cytotoxic to several type of cells (216,217). 
It is suggested that it has teratogenicity or chromosomal 
effects, but no strong evidence is available to support this 
hypothesis (213) although (214) has demonstrated that fuS-x 
has genotoxic potentials when administered or exposed at low 
levels. Bony et al (210) concluded that due to the lack of strong 
evidence on fuS-x carcinogenicity in both animal and man, 
fuS-x is not considered as a carcinogenic agent.
Zearalenone. Zearalenone (fig. 10) shows hormonal 
activity in many animal species which makes it genotoxic, 
carcinogenic or both at the same time (218), and it can impose 
changes in the reproductive organs and systems of many 
laboratory animals such as mice, rats and different domestic 
animals such as horses (205). Due to this ability, it is hypothe-
sized that Zearalenone can be involved in causing reproductive 
organ cancer in both humans and animal. Zearalenone was 
found to be carcinogenic in mice and capable of causing hepa-
tocellular adenomas and pituitary tumors (205). More work 
is needed in order to confirm its carcinogenicity in humans. 
Despite its toxicity and carcinogenicity, Zearalenone is used to 
increase the meat production in cattle in some countries, and 
it is forbidden in other countries like some European coun-
tries (218). That is most probably due to the lack of evidence or 
data that supports its toxicity and carcinogenicity in humans 
and animal (219).
A high incident of esophageal cancer was reported in 
areas known to have mycotoxin contamination that includes 
zearalenone and the ability of this mycotoxin in inducing 
hyperkeratotic papillomatous in the forestomach of a rat 
esophageal squamous epithelium (220) suggested the involve-
ment of this mycotoxin in causing and developing a tumor in 
the digestive tract (221-224). When cultured vero cells and 
mouse bone marrow were treated with zearalenone, the myco-
toxin induces the formation of micronuclei, the development 
of clastogenicity and induces genotoxicity (225). Zearalenone 
has a DNA-attacking ability (141).
In an experiment to demonstrate the effect of estrogen 
present in the feed of animals, Zearalenone was found to induce 
mammary tumor in C3hAvyfB mice and further studies need 
to be conducted in order to confirm wether Zearalenone has 
cancer inducing ability or carcinogenic effects on target organs 
like diethylstilbestrol and the steroidal estrogens (226). A study 
was conducted on NTP mouse where the mice were given a 
dose of Zearalenone through food, and the result of this study 
showed the ability of Zearalenone in inducing hepatocellular 
adenomas in the female mice. Zearalenone was also found to 
cause DNA damage in Bacillus subtilis and it showed DNA 
adducts in female mice kidney and liver (227,228). Finally, it 
was shown that the results of this study confirmed the geno-
toxicity and the ability of zearalenone to induce hepatocellular 
adenomas in mice but not in rats (227). Since there is evidence 
to prove that these result can relate to humans, these results 
can be used to hypothesize the involvement of Zearalenone in 
developing liver, kidney and other types of cancer in humans.
6. Mycotoxin research gaps and the recommended new 
research areas
Many studies were conducted on the effect of mycotoxins 
on the biological system and their carcinogenicity-toxicity 
as mentioned before in this study but unfortunately, many of 
these studies were done on animal models and the action of 
mycotoxins in human biological systems were simply hypoth-
esized and no solid data were generated for many mycotoxins. 
As mentioned earlier, food products that can be contaminated 
with mycotoxins include cereal (maize, sorghum, pearl millet, 
rice, and wheat), oil seeds (ground nut, soybean, sunflower, 
cotton), spices (chilies, black pepper, coriander, turmeric, and 
ginger), tree nuts (almonds, pistachio, walnuts, and coconut) 
and finally milk (27,229-232). In addition, aflatoxins are found 
in the contaminated tobacco leaves (233). Finally, aflatoxins 
can be present in dry soil, which can move to the underground 
water with rain and be ingested by humans and animals through 
the drinking water (234). All these food sources and food 
products are the basic food items for people around the world 
which make their contamination with mycotoxin considered 
as a major health concern for their high carcinogenic-toxic 
nature and potential in both animals and humans biological 
system (40).
It is well known that the availability of safe and edible 
food is essential for sustaining humans and animal life and 
the fact that food shortage was the reason behind provoking 
many wars, people started to store and preserve food on large 
scale for longer time to avoid any shortage that aid in storing 
and transporting food items in different forms of packages 
and containers. That happened right before the Second World 
War and continues to grow exponentially after that (235). 
As the food industry became bigger after the Second World 
War (236), packaging and distribution importance grew 
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exponentially, and both processes became more susceptible 
to different weather conditions and the exposure to different 
microorganisms that may lead to food spoilage and contami-
nation with different microorganisms including fungi and the 
mycotoxins they produce (237,238). An increase in the rates of 
testicular cancer incidences across Europe was observed post 
Second World War (239) and the reasons for it was not clear. 
It can hypothesized that the reasons for it can be linked to 
the increase in the stored food contamination with mycotoxins 
that can lead to testicular cancer (173,174).
During and after the 2nd World War, there was an increase 
in the incidents of lung cancer in Coastal Georgia specifically 
between males working in the shipyards in a warm and humid 
conditions (240). Due to the high humidity, tobacco leaves 
were contaminated with Aspergillus flavus that produces 
aflatoxin B1 (23) which is a highly carcinogenic substance 
that was associated with different cancer types including 
lung cancer (161). No solid data were generated to support 
the induction of human lung cancer by aflatoxin B1 but it can 
be hypothesized that their involvement induce lung cancer 
since aflatoxin B1 inactivates GSTM1-1 that is responsible 
for the production of cytosolic Glutathione S-transferases 
that helps in detoxifying several carcinogenic electrophiles 
that cause lung cancer, hence additional lab experiments 
need to be conducted to confirm this involvement. Moreover, 
aflatoxin B1 was suggested to cause primary lung cancer also 
through the activation of GSTM1-1 (161) and this mycotoxin 
can be inhaled and cause a direct effect on the lung cells (157) 
and that can indicate the effect of mycotoxin in causing lung 
cancer, but very limited data were collected in this area and 
further studies need to be conducted.
Another study was conducted in Norway where it was 
found that the rates of breast cancer increased greatly during 
and after World War II and the reasons were not conclu-
sive, and they linked the increase in the breast cancer rate 
to the change in the people's lifestyle (241). The fact that 
eating habits and food storage and transportation changed 
greatly during and after World War II, the possibility of 
food contamination increased greatly and fungal contami-
nation started to become a common phenomenon in stored 
food and mycotoxin contamination could spread widely. 
Mycotoxins such as Aflatoxin B1 (Fig. 1) and Ochratoxin A 
(Fig. 5) were confirmed to suppress tumor suppressor genes 
BRCA1, BRCA2 and P52 (2,172). A hypothesis can be made 
to conclude the involvement of mycotoxin in inducing breast 
cancer around the world, but there is a huge gap in this area 
and additional laboratory work need to be established to 
confirm it. In addition, HER-1, HER-2 and the c-myc onco-
genes were found to be overexpressed in many breast cancer 
cases (242-244) and that can also be related to the involve-
ment of mycotoxins since they have the ability to impose 
different changes in the human genome but further studies 
need to be conducted.
Patulin (fig. 6) causes an inactivation of the active site 
of protein tyrosine phosphatase (PTP) and this protein is a 
key regulator of intestinal epithelial barrier function and the 
active site of PTP contains a cysteine residue (Cys215). This 
is important and required for phosphatase activity and sulf-
hydryl-reacting compounds such as acetaldehyde decrease 
the transepithelial resistance (TER) through a covalent 
modification of cysteine residue Cys215 of the protein tyrosine 
phosphatase. This toxicity can lead to damage in the intestinal 
cells that eventually may lead to intestinal and stomach cancer.
Some mycotoxins such as fumonisins can cause neuro-
degenerative disease (187,188). Their mode of action can be 
further studied to detect if they are involved in causing brain 
cancer and tumors by studying their effect on different genes 
in the brain. fumonisins were also found to be involved in the 
development of neural tube defects among Mexican-American 
woman in south Texas which is characterized by defects in 
the brain, spine, or spinal cord of fetus in the first month of 
pregnancy (190) this involvement can also be used to hypoth-
esize the involvement of fumonisins in causing brain cancer 
in humans and further studies need to be conducted to support 
and confirm this hypothesis.
Zearalenone mycotoxin (f-2) major effects will be on the 
reproduction ability in females where they effects the repro-
ductive organs, and their functions which will eventually lead 
to a medical condition called hyperestrogenism (137) and this 
phenomenon can be studied further to uncover if f-2 can be 
involved in developing ovary cancer. finally, fumonisin B1 
was found to cause inhibition in the production of ceramide 
synthase which will lead to enhancing tumor necrosis factor α, 
production leading to apoptosis (143) and the ability of this 
mycotoxin to induce apoptosis can be used to detect the 
involvement of this mycotoxin in causing skin cancer.
7. Conclusions
Many mycotoxins have the ability of causing major changes 
to the human genome which may result in the development 
of cancer, and many other mycotoxins are capable of causing 
highly toxic effects on the biological systems they enter. The 
different mycotoxins that can cause cancer are Aflatoxin B1, 
Citrinin, fumonisins, Patulin, Trichothecene and Zearalenone. 
The role of mycotoxins in causing cancer will vary with the 
type of mycotoxin and it will depend on the mode of action 
within the biological system.
Aflatoxin B1 (Fig. 1) can penetrate the cell membrane and 
attach to its DNA where it causes irreversible mutations. As 
soon as aflatoxin B1 enters the cells, they are metabolized by 
cytochrome P450, to aflatoxin-8, 9-epoxide which is highly 
reactive and unstable and requires the binding to a DNA or to 
the protein molecule in order to become more stable and it will 
form aflatoxin-N7-guanine that cause GC to TA transversion 
mutations which will directly affect the cell cycle by affecting 
the P53 gene which encodes for tumor suppressor protein that 
inhibits the development of cancer.
Ochratoxin A (fig. 5) can cause an alteration of gene 
expression that results in affecting calcium homeostasis which 
will disrupt the different pathways regulated by the hNf4α 
and Nrf2 in the kidney, influence the expression of genes that 
are involved in DNA synthesis and repair, in response to DNA 
damage and it has a very small influence on the genes that are 
responsible for apoptosis. Ochratoxin A can cause genotoxicity 
by forming a DNA adduct and single cell death. furthermore, 
Ochratoxin A can increase phosphorylation of a typical-PKC 
which in turn will lead to a downstream activation of ERK1 
and ERK 2 and their substrate ELK1, ELK2 and p90RSK 
where PKC and the MEK-ERK MAP-kinase pathways acti-
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vated by Ochratoxin A are involved in cell proliferation, cell 
survival, anti-apoptotic activity and most importantly renal 
cancer development. Ochratoxin A is suggested to have a 
renal carcinogenesis effect. Its mode of action is by means 
of direct genotoxicity through covalent DNA adduct forma-
tion. The effects of aflatoxin B1 and Ochratoxin A in causing 
breast cancer and lung cancer are demonstrated in only a few 
studies and additional studies need to be conducted in order to 
confirm the course of action which will help in controlling and 
reducing the rates of these cancers which are considered as the 
most common cancers in the world.
Citrinin produced micronuclei and DNA migration and 
it has the potential of inducing micronuclei. Citrinin would 
cause DNA damage which would increase the risk of cancer 
in humans. Citrinin can induce chromosomal aberrations in 
both human and rat livers and it can cause complex transloca-
tions within the cellular DNA at a high frequency and it is 
capable of inducing defects in chromosomal coiling which 
may lead to the formation of DNA adducts. Apart from this, it 
can cause DNA fragmentation and apoptosis and finally, it can 
cause a mitotic arrest and CREST-positive micronuclei where 
it will induce the formation of micronuclei containing a whole 
chromosome or chromatids and will eventually lead to cancer 
development.
fumonisins (fig. 4) are capable of inhibiting the biosyn-
thesis of sphingosine and the complex sphingolipids by 
inhibiting the enzyme ceramide synthase. That, in turn, will 
lead to the increase in free sphinganine and the free sphingoid 
bases which are toxic in cells, and that will inhibit the growth, 
increase cell death, and initiate involvement in mitogenicity 
that would lead to the development of cancer.
Patulin (fig. 6) will cause an inactivation of the active 
site of protein tyrosine phosphatase (PTP) and this protein 
is a key regulator of intestinal epithelial barrier function. 
The active site of PTP contains a cysteine residue (Cys215) 
which is important and required for phosphatase activity 
and sulfhydryl-reacting compounds such as acetaldehyde. 
Acetaldehyde decreases the transepithelial resistance (TER) 
through a covalent modification of cysteine residue Cys215 
of the protein tyrosine phosphatase and this toxicity can lead 
to damage in the intestinal cells that may eventually lead to 
intestinal and stomach cancer.
T-2, a trichothecene mycotoxin is capable of inducing 
breaks in the DNA of lymphocytes when administered in vivo 
and in vitro once the fibroblast cells are treated with this myco-
toxin combined with 3h thymidine. In addition, Nivalenol, a 
trichothecene mycotoxin is also involved in causing chromatid 
exchange in cells and it can cause DNA damage and that 
makes it a potential genotoxic agent. finally, trichothecene 
mycotoxin can inhibit the proliferation and Ig production in 
the mitogen-stimulated human lymphocytes and it can induce 
apoptosis, the migration of sister chromatids as well as cause 
protein synthesis inhibition. The action of T-2 and Nivalenol 
on a cellular level can be responsible for the development of 
tumors and cancer.
Zearalenone (fig. 10) shows hormonal activity in many 
animal species which makes it genotoxic, carcinogenic or both 
at the same time, and it can impose changes in the reproduc-
tive organs and systems of many laboratory animals such as 
mice and rats and different domestic animals such as horses. 
Thus, Zearalenone is capable of causing reproductive organ 
cancer in both man and animal.
The cancers that can be caused by mycotoxins include liver 
cancer, kidney cancer, esophageal cancer, lung cancer, renal 
cancer, breast cancer, testicular cancer, stomach cancer and 
reproductive organ cancer. Considering the danger caused by 
mycotoxins, additional investigations need to be conducted to 
confirm the ability of each mycotoxin in inducing cancer, as 
stated above.
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